Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates

References

• Centers for Disease Control and Prevention. Understanding the epidemic; 2020. https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed January 10, 2020.
   Google Scholar
• Larochelle MR, Stopka TJ, Xuan Z, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and mortality. Ann Intern Med. 2019;170(6):430–431.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Davoli KJ. M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;23(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(16):1596–1597.
   PubMedGoogle Scholar
• Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–1513.
   PubMed Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: A systematic review. Addiction. 2018;113(7):1188–1209.
   PubMed Web of Science ®Google Scholar
• Williams AR, Nunes EV, Bisaga A, et al. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018;91:57–68.
   PubMed Web of Science ®Google Scholar
• Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760–1772.
   PubMed Web of Science ®Google Scholar
• Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–26.
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M. Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff. 2019;38(1):14–23.
   PubMed Web of Science ®Google Scholar
• Finlay AK, Morse E, Stimmel M, et al. Barriers to medications for opioid use disorder among veterans involved in the legal system: a qualitative study. J Gen Intern Med. 2020;35(9):2529–2536.
   PubMed Web of Science ®Google Scholar
• Rawson RA, Rieckmann T, Cousins S, McCann M, Pearce R. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system. Prev Med. 2019;128:105785.
   PubMed Web of Science ®Google Scholar
• Jacobson N, Horst J, Wilcox-Warren L, et al. Organizational facilitators and barriers to medication for opioid use disorder capacity expansion and use. J Behav Health Serv Res. 2020;47(4):439–448.
   PubMed Web of Science ®Google Scholar
• Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157.
   PubMed Web of Science ®Google Scholar
• Livingston JD, Adams E, Jordan M, MacMillan Z, Hering R. Primary care physicians' views about prescribing methadone to treat opioid use disorder. Subst Use Misuse. 2018;53(2):344–353.
   PubMed Web of Science ®Google Scholar
• Vogel M, Nordt C, Dursteler KM, et al. Evaluation of medication-assisted treatment of opioid dependence-the physicians' perspective. Drug Alcohol Depend. 2016;164:106–112.
   PubMed Web of Science ®Google Scholar
• Spencer NE, Taubenberger SP, Roberto R, Krishnamurti LS, Chang JC, Hacker K. “Stories of starting”: Understanding the complex contexts of opioid misuse initiation. Subst Abus. 2021:1–16. doi:10.1080/08897077.2021.1878084
   Web of Science ®Google Scholar
• Taubenberger S, Spencer N, Chang JC, et al. A rapid-cycle assessment strategy for understanding the opioid overdose epidemic in local communities. Subst Abus. 2021:1–15. doi:10.1080/08897077.2021.1891601
   Web of Science ®Google Scholar
• Allegheny County Department of Human Services. Opioid-related overdose deaths in Allegheny County: Report and maps; 2018. https://www.alleghenycountyanalytics.us/index.php/2018/02/15/opioid-related-overdose-deaths-allegheny-county-report-data-visualizations/. Accessed August 5, 2020.
   Google Scholar
• Simpson AT. Health and renaissance: Academic medicine and the remaking of modern Pittsburgh. Journal of Urban History. 2015;41(1):19–27.
   Web of Science ®Google Scholar
• U.S. General Services Administration. Allegheny County hospitals; 2018. https://catalog.data.gov/dataset/allegheny-county-hospitals. Accessed July 12, 2020.
   Google Scholar
• Fitch C, Stimson GV, Rhodes T, Poznyak V. Rapid assessment: an international review of diffusion, practice and outcomes in the substance use field. Soc Sci Med. 2004;59(9):1819–1830.
   PubMed Web of Science ®Google Scholar
• Stimson GV, Fitch C, DesJarlais D, et al. Rapid assessment and response studies of injection drug use: knowledge gain, capacity building, and intervention development in a multisite study. Am J Public Health. 2006;96(2):288–295.
   PubMed Web of Science ®Google Scholar
• Patton MQ. Qualitative research evaluation methods. 3rd ed. Thousand Oaks, CA: Sage; 2002.
   Google Scholar
• Thomas DR. A general inductive approach for analyzing qualitative evaluation data. American Journal of Evaluation. 2006;27(2):237–246.
   Web of Science ®Google Scholar
• Glaser BG. Open coding descriptions. Grounded Theory Review. 2016;15(2):108–110.
   Web of Science ®Google Scholar
• Cascio MA, Lee E, Vaudrin N, Freedman DA. A team-based approach to open coding: considerations for creating intercoder consensus. Field Methods. 2019;31(2):116–130.
   Web of Science ®Google Scholar
• Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398–405.
   PubMed Web of Science ®Google Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77–101.
   Google Scholar
• Sells SB. Methadone maintenance in perspective. Journal of Drug Issues. 1977;7(1):13–22.
   Web of Science ®Google Scholar
• Kennedy-Hendricks A, Barry CL, Gollust SE, Ensminger ME, Chisolm MS, McGinty EE. Social stigma toward persons with prescription opioid use disorder: associations with public support for punitive and public health-oriented policies. Psychiatr Serv. 2017;68(5):462–469.
   PubMed Web of Science ®Google Scholar
• Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence. A current perspective. West J Med. 1990;152(5):588–599.
   PubMedGoogle Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
   PubMed Web of Science ®Google Scholar
• Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B. “It takes your heart”: the image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict. 1985;20(11–12):1751–1771.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Opioid overdose: guides and meeting reports; 2019. https://www.cdc.gov/drugoverdose/pubs/guides-meeting-reports.html. Accessed November 17, 2020.
   Google Scholar
• Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–635.
   PubMed Web of Science ®Google Scholar
• Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015;52:48–57.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947–1954.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. TIP 63: medications for opioid use disorder; 2018. https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002. Accessed September 14, 2020.
   Google Scholar
• Sorrell TR, Weber M, Alvarez A, et al. From policy to practice: pilot program increases access to medication for opioid use disorder in rural Colorado. J Subst Abuse Treat. 2020;114:108027.
   PubMed Web of Science ®Google Scholar
• Huhn AS, Dunn KE. Why aren't physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.
   PubMed Web of Science ®Google Scholar
• Levin FR, Bisaga A, Sullivan MA, Williams AR, Cates-Wessel K. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. Am J Addict. 2016;25(8):603–609.
   PubMed Web of Science ®Google Scholar
• Meyers T. Things under the tongue: pharmacotherapy, its intersections and its afterlife in urban America. The Johns Hopkins University. Proquest Dissertations Publishing; 2009.
   Google Scholar
• Weinstein ZM, Gryczynski G, Cheng DM, et al. Tapering off and returning to buprenorphine maintenance in a primary care office based addiction treatment (OBAT) program. Drug Alcohol Depend. 2018;189:166–171.
   PubMed Web of Science ®Google Scholar
• Huhn AS, Hobelmann JG, Strickland JC, et al. Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States. JAMA Netw Open. 2020;3(2):e1920843.
   PubMed Web of Science ®Google Scholar
• Matusow H, Dickman SL, Rich JD, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473–480.
   PubMed Web of Science ®Google Scholar
• Saunders E, Metcalf SA, Walsh O, et al. “You can see those concentric rings going out”: Emergency personnel's experiences treating overdose and perspectives on policy-level responses to the opioid crisis in New Hampshire . Drug Alcohol Depend. 2019;204:107555.
   PubMed Web of Science ®Google Scholar
• Hoffman KA, Baker R, Kunkel LE, et al. Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. BMC Health Serv Res. 2019;19(1):862.
   PubMed Web of Science ®Google Scholar
• Trowbridge P, Weinstein ZM, Kerensky T, et al. Addiction consultation services – linking hospitalized patients to outpatient addiction treatment. J Subst Abuse Treat. 2017;79:1–5.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–1644.
   PubMed Web of Science ®Google Scholar
• Hinde JM, Mark TL, Fuller L, Dey J, Hayes J. Increasing access to opioid use disorder treatment: assessing state policies and the evidence behind them. J Stud Alcohol Drugs. 2019;80(6):693–697.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Use of medication-assisted treatment in emergency departments; 2021. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/pep21-pl-guide-5.pdf. Accessed August 9, 2021.
   Google Scholar
• Cance JD, Doyle E. Changes in outpatient buprenorphine dispensing during the COVID-19 pandemic. JAMA. 2020;324(23):2442–2444.
   PubMed Web of Science ®Google Scholar
• Green TC, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment. Subst Abus. 2020;41(2):147–149.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency; 2020. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf. Accessed August 10, 2021.
   Google Scholar
• Allegheny County Department of Human Services. The journey into Allegheny County’s substance use disorder treatment system: using human-centered design to learn more about people’s experiences with entering treatment; 2018. https://www.alleghenycountyanalytics.us/wp-content/uploads/2019/01/18-ACDHS-24_SubstanceUse_012219.pdf. Accessed August 5, 2020.
   Google Scholar